New Delhi, May 5 -- In a landmark collaboration, pharmaceutical giant Eli Lilly has partnered with San Diego-based biotech firm Creyon Bio to develop next-generation RNA-targeted therapies. The deal includes a $13 million upfront payment to Creyon, comprising both cash and equity investment, with the potential for over $1 billion in milestone payments contingent on the achievement of specific development and commercialization goals.

Harnessing AI for Oligonucleotide Therapeutics Central to this partnership is Creyon Bio's proprietary AI-Powered Oligo Engineering Engine, a platform designed to streamline the discovery and optimization of oligonucleotide-based drugs. Oligonucleotides are short strands of synthetic DNA or RNA that can modul...